Open-label, phase I dose-escalation study of sodium selenate, a novel activator of PP2A, in patients with castration-resistant prostate cancer

BACKGROUND: Angiogenesis is fundamental to the progression of many solid tumours including prostate cancer. Sodium selenate is a small, water-soluble, orally bioavailable activator of PP2A phosphatase with anti-angiogenic properties. METHODS: This was a dose-escalation phase I study in men with asym...

Descripción completa

Detalles Bibliográficos
Autores principales: Corcoran, N M, Hovens, C M, Michael, M, Rosenthal, M A, Costello, A J
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2010
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2939789/
https://www.ncbi.nlm.nih.gov/pubmed/20648008
http://dx.doi.org/10.1038/sj.bjc.6605798

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2939789/
https://www.ncbi.nlm.nih.gov/pubmed/20648008
http://dx.doi.org/10.1038/sj.bjc.6605798

Ejemplares similares